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Abstract  
Background 
By taking advantage of the preferential engraftment of exogenously administered 
mesenchymal stem cells (MSCs) in the tumoral stroma, we have demonstrated how 
those cells can be efficiently used as Trojan horses harbouring plasmonic hollow gold 
nanoparticles (HGNs) used in photothermal therapy in vivo. 
Methods 
In order to understand the kinetics of the cell internalization process and to calculate 
the sub-cytotoxic doses of those nanoparticles on MSCs, we have used confocal and 
scanning-electron microscopy and the Alamar Blue test, respectively. In a first 
experiment direct intratumoral injections of the nanoparticle-laden cells were used to 
demonstrate the efficiency of the photothermal therapy. In a second experiment, the 
therapy efficacy was evaluated either using intravenously administered free plasmonic 
nanoparticles or the same nanoparticles internalized within MSCs on subcutaneous 
xenograft tumors. 
Results 
Under the same irradiation conditions, the ablated surface area after photothermal 
treatment was 1.5 times larger when using one single dose of intravenously 
administered HGN-laden-MSCs compared to the administration of free HGNs. 
Conclusions 
MSCs are postulated as a better carrier for therapeutical nanoparticles compared to the 
conventional extravasation into the tumor driven by the enhanced permeability and 
retention (EPR) effect. Reduced immunogenicity, selective over-accumulation and 
homogeneous distribution of the nanoparticles around the tumor were observed when 
using MSCs as “Trojan horses” probably due to the ability of the MSCs to migrate 
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and integrate homogeneously at sites of inflammation. All these data give enough 
evidence to consider MSCs as an ideal carrier for nanoparticle-based therapies. 
 
Keywords: Mesenchymal stem cells, cancer, nanoparticles, hyperthermia; phothermal 
therapy; EPR. 
 
Background  
Cancer is the leading cause of death worldwide, with 7.6 million deaths in 2013; data 
which are projected to continue rising with an estimated 13.1 million deaths in 2030 
according to WHO.[1]  The increase in the life expectancy, the presence of mutagenic 
agents in the environment, and the lack of healthy habits could influence this high 
incidence of the disease.[2] 
Preventive medicine, surgery, chemotherapy and radiotherapy are the main 
approaches to defeat cancer, but they have major side effects because those 
therapeutical approaches affect both tumoral and healthy tissues. Chemotherapeutic 
drugs in particular fall short due to not only their unwanted side effects in healthy 
tissues but also due to the potential development of multidrug resistance and their low 
permeance towards the interior of the tumor core due to its high interstitial pressure. 
Therefore, there is a need to develop new, more effective and safer treatments able to 
reach homogeneously all the tumoral mass, including the central hypoxic regions.  
One of the emerging therapies proposed in recent years involves the generation of 
hyperthermia or tumoral ablation using magnetic or near-infrared (NIR) responsive 
nanoparticles which generate localized heat by the use of alternating magnetic fields 
or near infrared (NIR) light, respectively. In this particular application, phototherapy 
consists on an increase in the local temperature (41-47°C) by using the heat 
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transmitted by the NIR-absorbing nanoparticles upon laser irradiation, leading to the 
apoptosis or necrosis of the tumor cells depending on the laser fluence, pulse 
frequency, wavelength of the irradiating light and irradiation time. Specifically, gold 
nanoparticles are good candidates to mediate this process because of their high light 
absorption efficiency, low cytotoxicity, good biocompatibility and their simple and 
scalable synthesis.[3] Hollow gold nanospheres (HGNs) are able to absorb energy in 
the NIR region of the electromagnetic spectrum and dissipate it as heat due to 
electron-electron and electron-phonon relaxations. In addition, between 650 and 1100 
nm the absorption and scattering of incident light in biological tissues is reduced. 
Therefore, in this way, external irradiation of tissues with single wavelength lasers in 
that region (i.e. 808 nm) produces heat only where the light-absorbing nanoparticles 
are embedded, reducing the characteristic side effects of other conventional 
treatments such as chemo- or radiotherapy and to other hyperthermia-based 
techniques (such as microwave ablation, magnetic fluid ablation, radiofrequency, and 
focused ultrasound therapy).[4] Compared to other plasmonic nanoparticles such as 
gold nanorods or core-shell SiO2-Au nanoparticles, HGNs are more efficient in 
photothermal therapy for shallow and deep cancers.[4] However, even though there 
are very efficient nanoparticles as transductors of the NIR light into heat, the use of 
generalized hyperthermia also produces damage in healthy cells and tissues, and 
therefore, it is important to obtain local hyperthermia exclusively at the tumor site 
which it is by no means an easy task.[5] The well known enhanced permeation and 
retention effect contributes to the passive over-accumulation of nanoparticles at the 
tumor [6] and selective accumulation can be further increased by the use of suitable 
antibodies or other recognition biomolecules (carbohydrates, peptides, nucleic acids, 
etc.) grafted to the external nanoparticle surface.[7] However, a selective 
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accumulation of nanoparticles requires sufficient circulation time in the bloodstream, 
but, as it is well known, nanoparticles are rapidly cleared by the macrophages of the 
reticulo-endothelial system[8] from circulation. To solve this problem, stealthing 
strategies (e.g. coating with layers of poly-ethylene glycol, biomimetic surface 
modifications (phosphatidylcholine), etc.) have been developed to increase their 
circulation life time.[8] In addition, nanoparticles could also be delivered using cells 
as carriers to evade the immune system recognition ability, in a so-called “Trojan 
horse” strategy.   
This concept of Trojan horse has been postulated in previous works using different 
nanoparticle-laden cells including dendritic,[9] macrophages[10, 11] and even T 
lymphocytes.[12] Compared to those previous vectors, bone marrow MSCs have a 
number of characteristics that make them superior, including their ability for self-
renewal, potential to differentiate into different tissues and ability to migrate and 
integrate at sites of inflammation or into tumors.[13-15] Although the complete 
mechanism of this phenomenon is still unknown, it is recognized that the release of 
cytokines in the tumor stroma and their interaction with cytokine and chemokine 
receptors present in the cell surfaces are involved in the migration of MSCs as well as 
the adequate hypoxic environment which does not impair their migration.[16] 
Nanoparticle transport inside MSCs directed against brain tumors was previously 
demonstrated, although, in that case MSCs were directly injected on site, being the 
MSCs observed afterwards in the tumor periphery.[17] Dwyer et al.[18] demonstrated 
a successful engraftment of MSCs at the site of both primary tumors and nodal cancer 
metastases after systemic administration in vivo, although no nanoparticle was carried 
in that case. 
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Moreover, MSCs present a great advantage in relation to solve some of the problems 
found during the nanoparticle-based injection alone such as the previously mentioned 
rapid immune response and low permeance towards the interior of the tumoral mass 
due to the high pressure gradient. Regarding to the immune response, the fact that 
they do not express MHC class II and have a very low expression of MHC class I,[16, 
19]  may favour the use of these cells in allografts. As it is also known that bone 
marrow MSCs are able to migrate to hypoxic areas,[16] here we propose the use of 
these cells as vectors for NIR-responsive nanoparticles to delivery treatment to the 
central hypoxic areas of tumors by applying optical hyperthermia.  
Since sub-cytotoxic doses of cell internalized HGNs are inert in the absence of laser 
irradiation, this would be a safe protocol that would allow to locally induce 
hyperthermia at the tumor site. Therefore, here we studied the in vitro and in vivo 
behaviour of intravenously injected HGNs and their antitumoral effect in the presence 
of laser light (808nm) compared to the same nanoparticles internalized within MSCs. 
Methods 
Synthesis of Hollow Gold Nanospheres.  
Nanoparticle synthesis was performed following the protocol described at Preciado-
Flores et al. [20] with slight modifications. Briefly, in a two-necked round-bottom 
flask 400 mL of distilled water, 400 µL of 0.4 M of cobalt chloride hexahydrate 
(CoCl2·6H2O) and 1.6 mL of 0.1 M sodium citrate trihydrate (Na3C6H5O7·3H2O) were 
added under an inert Ar atmosphere to avoid a premature Co oxidation. After 40 
minutes, 2 mL of a 1 wt. % solution of poly (vinylpyrrolidone) (PVP) with an average 
Mw of 55000 Da and 400 µL of 1.0 M sodium borohydride (NaBH4) were added. The 
color change from pale pink to brown was indicative of the cobalt nanoparticle 
formation. Afterwards, 120 mL of distilled water and 180 µL of 0.1M chloroauric 
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acid trihydrate (HAuCl4·3H2O) were mixed with 360 mL of the previous cobalt-based 
dispersion used as a sacrificial template, to promote the formation of CoCl2 and the 
reduction of Au
3+
 rendering hollow Au-based shells. 
The resulting HGNs were coated with poly-ethylene glycol by using an excess of 
monofunctional poly(ethylene glycol)methyl-ether-thiol (PEG, 1000 Da MW), to take 
advantage of the strong chemical bond between Au and S[21]. Any excess of unbound 
PEG was removed by dialysis. 
The concentration of the final dispersion was adjusted by centrifugation at 10000 rpm 
for 10 minutes and both HGNs and PEG-HGNs were thoroughly characterized by 
transmission electron microscopy, scanning electron microscopy, thermogravimetric 
analysis (TGA) and UV-visible spectroscopy. 
Cell culture conditions 
Murine mesenchymal stem cells (MSCs), HeLa cells and human U251MG glioma 
cells were purchased from Lonza and Cancer Research-UK cell services, respectively. 
MSCs were cultured in Dulbecco’s modified Eagle’s F-12 medium (DMEM F-12, 
GIBCO) with 10% fetal bovine serum (FBS, GIBCO), 1% penicillin/streptomycin and 
1% amphotericin and maintained at 37°C in a 5% CO2-humidified atmosphere under 
hypoxic conditions (3% O2). For culturing U251MG and HeLa cells Dulbecco’s 
modified Eagle’s medium (DMEM, GIBCO) with 10% fetal bovine serum (FBS, 
GIBCO), 1% penicillin/streptomycin and 1% amphotericin were used under normoxic 
conditions.   
HGNs cytotoxicity evaluation 
The Alamar Blue is a colorimetric assay to evaluate cell viability and cytotoxicity 
based on the reduction of resazurin to resorufin by mitochondrial oxidoreductases. 
During the evaluation, MSCs were seeded into 96-well culture plates at a 
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concentration of 5 x 10
3
 cells per well in 100 µL of the above mentioned medium. 
After incubation at 37°C in a 5% CO2-humidified incubator under hypoxic conditions 
for 24 h, the medium was changed to 100 µL of fresh medium enriched with HGNs 
(5, 10, 20, 50 and 100 µg mL
-1
) or with PEG-HGNs (20, 50, 100 and 500 µg mL
-1
) 
and cells were cultured for another 24, 48 and 72 h. At these different time points 
cells were washed with PBS and then treated with 10% (v/v) of resazurin dye reagent 
prepared in DMEM F-12 medium. Culture plates were then placed in a 37°C/5% CO2 
incubator under hypoxic conditions for 2 h. Afterwards, fluorescence was evaluated at 
530/590 nm excitation/emission wavelengths using a Synergy HT (Biotek) plate 
reader. 
Cellular uptake of nanoparticles 
Confocal microscopy characterization (Spectral Confocal Microscope Leica TCS 
SP2) was carried out to evaluate cellular uptake and trafficking on the cells studied. In 
this case, cells were seed at a density of 3 x 10
4
 cells on 20 mm cover slips (in a 24-
well plate) and allowed to grow for 2 days. Then HGNs (50 µg mL
-1
) in DMEM F-12 
were added keeping the incubation for 1 day. Finally, cells were fixed with para-
formaldehyde 4% and stained with phalloidin to label the cytoplasmic actin. HGN-
based agglomerates were directly observed by reflection in the confocal microscope 
without the need of using fluorophores. For obtaining the SEM Dual-Beam (FEI Nova 
200 Dual-Beam SEM/FIB) images cells were dehydrated, dyed and embedded in resin 
before observation. The electronic observation was combined with a focused ion 
beam (FIB) to visualize and cut the MSCs. Gallium was used as liquid metal ion 
source to produce cross-sections of the adherent cells. Both the ion column and the 
electron column operated at accelerating voltages of 30kV. 
 - 9 - 
Flow cytometry 
Nanoparticle internalization was evaluated by using flow cytometry. In this case, 5 
mL of HGNs or PEG-HGNs (1mg·mL
-1
) dispersions were maintained under agitation 
with Rhodamine 123 (1 mg·mL
-1
, 25µL) for 1 hour. To remove any potential unbound 
dye, each dispersion was then dialyzed for two days against distilled water. 
Afterwards, 1 x 10
6
 cells were incubated with the corresponding Rhodamine-labeled 
nanoparticles and at different time points cells were washed twice with PBS and 
trypsinized. After centrifugation, cells were then resuspended in PBS (1 x 10
6
 
cells·mL
-1
) and analyzed by flow cytometry with an ImageStreamX  (Seattle, WA, 
USA). 
Cell irradiation 
 To study the laser effect in the cells containing sub-cytotoxic doses of internalized 
HGNs, MSCs (50000-100000 cells/well) were incubated with the HGNs (0,02 or 0,05 
mg·mL
-1
) during one day. After that, those adherent cells were washed twice with 
PBS, to ensure that any possible heating would not be produced by free, non-
internalized nanoparticles present in the medium. MSCs were then irradiated in 
DMEM F-12 during 30 minutes with a NIR laser (808 nm) at 1W·cm
-2
 of irradiance. 
Then, irradiated cells were incubated in a 37°C/5% CO2 incubator under hypoxic 
conditions for 48 h. After that time cells were incubated with the LIVE/DEAD 
fluorescent reagent (Life Technologies) following the manufacturer's protocol and 
visualized under an inverted fluorescence microscope (Olympus IX81). The Alamar 
Blue assay was also used in order to compare the viability of the irradiated cells 
with and without internalized nanoparticles.  
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In vivo experiments 
All procedures were carried out under Project License PI 14/11 approved by the in-
house Ethic Committee for Animal Experiments from the University of Zaragoza. The 
care and use of animals were performed accordingly with the Spanish Policy for 
Animal Protection RD53/2013, which meets the European Union Directive 2010/63 
on the protection of animals used for experimental and other scientific purposes. 
For these experiments six- to eight-week-old female BALB/c nu/nu mice (Harlan 
Iberica) were used. All the animals received subcutaneous injections of 5 x 10
6
 
U251MG cells or HeLa cells suspended in 200 l of PBS for the generation of 
subcutaneous xenograft tumors. When the tumor size was >0.5cm
2
, the animals were 
divided into groups of four mice per group. 
In the first experiment direct intratumoral injections of the nanoparticle-laden cells 
(HGNs and PEG-HGNs) were used to demonstrate the efficiency of the photothermal 
therapy, with five experimental groups. In this case, all groups were injected with 5 x 
10
6
 HeLa cells in one flank of the mouse for tumor induction. Group 1 included 
control animals which did not receive any treatment; Group 2 received laser 
irradiation but not HGNs injection; Group 3 received HGNs injection (50µg) but not 
laser irradiation;  Group 4 received HGNs (50µg) carried by 10
6
 MSCs and laser 
irradiation and Group 5 received both HGNs (50 µg) and laser. After one day of 
nanoparticle or MSC administration these two last groups and the control were 
irradiated with a NIR-laser (808nm) at an irradiance of 1W·cm
-2
 during 5 min. Tumor 
size was periodically evaluated by using a caliper up to 15 days after irradiation. 
The second experiment was aimed to assess the efficiency of MSCs as carriers of 
HGNs compared to conventional intravenous administration of plasmonic 
nanoparticles. To this end, we divided the animals into four groups. The first group 
served as control. The second group received an intravenous injection of 100 µg PEG-
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HGNs in 100 µl of PBS through the tail vein. The third and fourth groups were 
injected with a suspension of 1 x 10
6
 MSCs separately loaded with 100 µg PEG-
HGNs in 100 µL of PBS.  Previously, cells were incubated with the PEG-HGNs for 
24 hours, and afterwards cells were washed, trypsinized and one million of MSCs 
containing nanoparticles were injected in the tail vein. 
One day after intravenous injection, the second and third groups were irradiated 
during 5 min with a NIR laser (808 nm) at 1W·cm
-2
 irradiance around all the tumoral 
area using a spot size larger than the tumor projected surface. The fourth group did 
not receive any laser irradiation. One week after intravenous injection the same dose 
of irradiation was used again following the same protocol. Tumor size evolution was 
evaluated over two weeks, until the tumor size was as big as the maximum size 
permitted by the University ethics committee. At this time point, animals were 
euthanized by CO2 inhalation. Tumor, brain, heart, kidney, liver, lung, spleen and 
gastrointestinal organs were collected from each animal for histopathological analysis 
and to evaluate gold bioaccumulation by ICP-MP-AES (4100, Agilent). 
Statistical analysis 
 All experiments were repeated in triplicate unless otherwise stated. Statistical 
evaluation of data was carried out using the SPSS Statistics software package (version 
17.0; IBM SPSS, Chicago, IL, USA). For the non-normal distributions the Mann-
Whitney U test was carried out. In all tests, P<0.05 was regarded as statistically 
significant.  
Tissue analysis 
Tissues were formalin-fixed and processed using routine histological methods. 
Sections of 3 μm were prepared after paraffin embedding and the slides were stained 
with hematoxylin and eosin. Microscopic lesions were described and a mitotic activity 
 - 12 - 
index was calculated by counting mitotic figures in ten consecutive high-power fields 
(HPF, 40x) from the most densely packed cellular area of the corresponding sample. 
To evaluate the proliferation index, an immunohistochemical analysis with Ki-67 
(FLEX monoclonal mouse anti-human Ki67 clone MIB-1 from DAKO, Denmark) 
was performed. Sections were incubated at room temperature with primary antibodies 
for 20 min at pH 6. The Envision Flex/Hrp Dako™ visualization system was used 
followed by a counterstaining with hematoxylin. Negative control sections received 
only antibody diluent instead of the primary antibody. Ki-67 expression was evaluated 
in all groups by counting positive and negative cells in ten consecutive HPF using the 
ImageJ software. On those images, the percentage of positive cells and their 
confidence interval (95%) were calculated. 
Organs and tumors were digested by dissolving them in hydrochloric:nitric acid (3:1) 
in a Teflon-lined digester using a Milestone ETHOS Plus Srl (Sorisole, Bergamo, 
Italy) microwave at 195 ºC.  Digested samples were diluted and gold content analyzed 
by ICP-MP-AES (4100, Agilent). Elemental gold standard (TraceCERT®, 1000 mg/L 
Au in hydrochloric acid, Fluka) was used for calibration. 
Results and Discussion 
Spherical hollow gold nanoparticles with 40,5 ± 7 nm in diameter (Figure 1A-C), 
were obtained after galvanic replacement using cobalt oxide nanoparticles as 
templates. Both HGNs and PEG-HGNs showed a characteristic localized surface 
plasmon resonance peak in the NIR region (Figure 1D). A slight blue shift was 
observed for the pegylated nanoparticles, possibly attributed to a different dielectric 
value in the interfacial double layer coating the nanoparticles in agreement with the 
previous literature.[22] The amount of PEG on the surface of the HGNs was 12 g·g-
1
, evaluated by TGA. 
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Compared to the control, PEG-HGNs did not decrease the cell viability at the 
doses tested (20, 50, 100 and 500 µg·mL
-1
) (Figure 2A). Our results are in agreement 
with previous studies which demonstrate that nanoparticle cytotoxicity is reduced 
after pegylation.[23] Also, this reduced cytotoxicity is in agreement with previous 
reports for MSCs harboring HGNs which also indicate that those nanoparticles did not 
affect MSCs differentiation.[24] A dose-dependent cytotoxicity was observed for the 
bare HGNs with a marked decrease in the cell viability at doses above 50 µg mL
-1
 
after 24h of incubation. It is important to point out that the apparent increase in cell 
viability observed after 72h of incubation is caused by the normalization selected for 
the control because we used the total number of viable cells remaining after 72 h as 
control. Obviously the total number of cells after 72 h was lower than the numbers 
obtained for the other times studied (0, 24 and 48h).  
Nanoparticle cell trafficking was evaluated by using confocal microscopy, 
scanning electron microscopy, flow cytometry and ICP. For the confocal studies, cells 
were permeabilized and stained with Draq5 to label the nuclei and with phalloidin-
Alexa488 to stain the cytoskeletal actin fibers. Due to their agglomeration in 
endocytic vesicles, HGNs were observed by using the reflection mode of the 
mciroscope exciting at 488 nm and collecting the emission between 479 and 498 nm. 
Z-stack orthogonal projections were carried out in order to demonstrate the presence 
of the nanoparticles inside the cytosol (Figure 3). HGNs internalization was also 
demonstrated by using SEM Dual-Beam (Figure 2B). Nanoparticles were clearly 
internalized forming aggregates inside vesicles, probably following the endosomal 
route, and the phenomenon was observed even after 7 days of co-incubation (Figure 
4). Differences in the internalization dynamics were found using flow cytometry by 
labelling the bare and PEGylate nanoparticles with rhodamine123. A maximum 
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nanoparticle internalization was reached at 24 and at 72 hours for the PEG-HGNs and 
the HGNs, respectively. It is important to point out that the chemical bond (Au-N) 
between rhodamine123 and gold through the lone pair electrons at the amino groups 
discards the potential detachment of the dye from the nanoparticles [25]. 
In the intratumoral (first) experiment, the treated groups were injected either with 
50g of HGNs or with one million of MSCs co-incubated with 50g of HGNs during 
72h. At this time point the amount of nanoparticles detected in the digested cells was 
33 g (evaluated by ICP). Tumors in Group 5 (HGNs+laser) reduced completely their 
size one week after irradiation (Figure 5). This result reflects the efficiency of the 
plasmonic HGNs in releasing heat locally after NIR irradiation. Since in this 
experiment, the HGNs were injected stereotactically, most of the HGN-based dose 
will be located and accumulated in the proximity of the tumor. Tumor sizes in Group 
4 (MSCs + HGNs +laser) strongly decreased ( 80% reduction in the projected area 
by day 12), but the tumor reduction was not as high as the one observed for Group 5 
due to the lower dose of plasmonic nanoparticles transported by the MSCs. In all 
other control groups tumor sizes increased. Figure 5a shows the evolution of the 
projected area of the tumor over time. Our results show that optical hyperthermia 
reduces the size of the tumor in only one week after treatment when a direct intra-
tumoral injection is used whereas, in other works, the combined use of intravenously 
administered NIR-responsive nanoparticles and chemotherapy produces also a 
complete tumor remission 20 days after irradiation.[26]. Therefore, the route of 
administration plays a key role in the dynamic process of over-accumulating a 
therapeutic dose of plasmonic nanoparticles in the tumoral area. 
On a second experiment (Figure 6) and after the demonstration that HGNs were 
able to mediate tumor regression, we administered the nanoparticles via intravenous 
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injection in the tail of the corresponding mouse. In this case, in order to reduce the 
number of animals we divided the animals into four groups. The control groups were 
the use of MSCs with PEG-HGNs but without any laser application and one 
additional control without any treatment. We used either PEG-HGNs or MSCs 
harboring PEG-HGNs in the other groups. As we mentioned before, MSCs can 
migrate to sites of injury and inflammation,[13] so we used these cells intravenously 
to analyze their capability in over-accumulating sub-cytotoxic doses in hypoxic and 
inflamed diseased tissues. Instead of bare HGNs, PEG-HGNs were used and delivered 
to tumors in order to reduce the recognition and fast clearance of the bare 
nanoparticles by the immune system. In this experiment we used U251MG glioma 
cells as a model tumor, because of the aggressiveness of this cell line, as we thought 
that the treatment on those tumors would be a major challenge than the previous 
HeLa-based model used in the first experiment. 
 All groups were injected with 5 x 10
6
 U251MG cells in one flank of the mouse for 
tumor induction. In this case, and compared to the previous experiment, we injected in 
the tail of the mouse a higher dose of PEG-HGNs (100 µg/per animal) or one million 
MSCs/animal loaded with 100 µg (evaluated by ICP) of PEG-HGNs, because the 
amount of gold per unit mass of nanoparticles coated with PEG was lower than that 
for the nanoparticles without coating due to the PEG corona. In this case, one day 
after the injection, tumors were irradiated. At this time point we could see a dark 
staining at the tumor site on mice where PEG-HGNs (either alone or vehiculizated) 
were used. Those observations did not take place for the control groups, indicating 
that part of the PEG-HGNs had already reached the tumor probably due to the EPR 
effect. These results are in agreement with previous works in which it was 
demonstrated that metal nanoparticles accumulate immediately in the tumor in vivo 
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using dynamic imaging studies.[27, 28] One week after the intravenous injection we 
irradiated the tumors again, because, as it was previously reported, it takes 
approximately one week for bone marrow MSCs to accumulate in the tumoral 
area.[29]  
Tumor development was followed until mice carried tumors at the ethically 
allowed size. At the end of the experiment the size of the tumor in the group with 
MSCs + PEG-HGNs and laser irradiation showed a higher decrease in the projected 
area compared to the group treated with PEG-HGNs and laser only without cells. This 
suggests that MSCs have been able to carry the nanoparticles to the tumors more 
efficiently than the well known extravasation achieved thanks to the EPR effect when 
using non-shuttled nanoparticles. The heterogeneity of the EPR effect in human 
cancers, including uncertainty in the degree of its effect in clinical cases has been 
widely reported in the literature.[30] Our results are in agreement with the work of 
Zhang et al.[24] who demonstrated a co-localization of human MSCs loaded with 
HGNs around tumoral blood vessels. In the group with PEG-HGNs and laser only the 
final tumor projected area was smaller than in the control corroborating the efficiency 
of the photothermal therapy. But, as we demonstrated, this efficiency can be boosted 
when using MSCs as carriers of the plasmonic gold nanoparticles. In the group with 
MSCs + PEG-HGNs without laser no significant differences were observed in the 
total tumor projected area compared to the one measured for the control. Smith et 
al.[30] have recently reported how intravenous administered carbon nanotubes might 
be uptaken by a specific subset of circulating inflammatory monocytes which carry 
them into the tumor. Therefore, not only the extravasation and over-accumulation due 
to the EPR effect are necessary to consider when taking about direct intravenous 
injection of nanomaterials but also a monocyte-based transport. However the ability 
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of MSCs to engraft in the tumoral stroma can be used to achieve higher doses of 
therapeutic nanoparticles in the target. 
The histological studies demonstrated that all the tumors showed an expansive, 
non-encapsulated, highly cellular neoplastic proliferation composed of extensive 
sheets of polyhedral, highly pleomorphic cells with atypical mitosis. Tumor cells 
showed round to ovoid nuclei, prominent nucleoli and a moderated, ill-defined 
eosinophylic cytoplasm. In those cells the stroma was formed by a scant connective 
tissue.  
 As shown in Figure 7, all groups (G1-G4) showed tumor masses with a central 
necrotic area. Interestingly, whereas G1 (control) and G4 (MSCs + PEG-HNPs 
without laser) tumors presented a single central area of necrosis, G2 (PEG-HNPs + 
laser) and G3 (MSCs + PEG-HNPs with laser) tumors showed additionally extensive 
multifocal necrotic areas within peripheral, viable tumor parenchyma. Regarding the 
mitotic activity index, G1 and G4 tumors showed a mean of 15 mitotic figures/10 
HPF whereas the mean for G2 and G3 tumors was 9 mitotic figures/10 HPF. Globally, 
these results might indicate increased treatment efficiency in those tumors containing 
nanoparticles and receiving laser irradiation. 
 The immunohistochemical analysis on the central area of the tumors recovered at the 
end of the experiment for Ki-67 expression indicated that G2 and G3 tumors exhibited 
lower expression of the protein when compared to G1 and G4 tumors (Table 1), being 
the difference on the protein expression between G2 and G3, G3 and G1, and G2 and 
G1, statistically significant (p<0.05). Ki-67 is a nuclear antigen expressed only in the 
different phases of cellular division, and therefore, it is widely used proliferation 
biomarker to estimate growth rates. In this regard, Ki-67 expression can also be used 
as a prognostic indicator of cerebral high-grade glioblastomas.[31] These histological 
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results support the possibility of a better prognosis for tumors subjected to this 
therapy, especially on the group treated with MSCs+ PEG-HGNs+ laser. 
No lesions were found in all remaining organs studied (brain, heart, kidney, liver, 
lung, spleen and gastrointestinal organs), denoting the lack of systemic injuries by the 
proposed localized treatment. ICP-OES analysis did not detect gold at any dose above 
the detection limit of the system (50g·L-1) in any of the groups probably because 
after 27 days (the total number of days from the injection) the nanoparticles were 
mostly cleared from the tumor site which represents a very positive result considering 
that nanoparticles with optimal clearance characteristics will minimize toxicity risks. 
This result was also not surprising considering that it has been reported that the gold 
content in the tumor tissue amounts to 1 % of its concentration in the injected 
suspensions.[32] 
Conclusions  
Hollow gold nanoparticles are efficient transducers in vivo of near infrared light 
into heat when stereotactically injected into subcutaneous HeLa cell-line xenograft 
tumors of when intravenously administered in the treatment of subcutaneous 
U251MG cell-line xenograft tumors. The heterogeneity of the EPR effect in human 
cancers leads to a variable distribution of plasmonic nanoparticles within the tumor, 
probably due to the degree of necrosis in solid tumors and a reduced lymphatic 
drainage. Also, it seems likely that in spite of the PEG coating, a fraction of the free 
HGNs injected intravenously will be detected and cleared by RES macrophages 
providing a relatively modest specificity towards the tumoral mass. Both problems 
were alleviated by using MSCs as carriers of those nanomaterials. 
 A successful subcytotoxic internalization of both bare and PEGylated hollow gold 
nanoparticles was demonstrated in murine MSCs using confocal and scanning 
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electron microscopy and also ICP analysis. Taking advantage of the tumor-homing 
ability of nanoparticle-loaded MSCs, a homogeneous nanoparticle distribution across 
the tumoral tissue was obtained and this phenomenon led to tumor eradication when 
applying photothermal therapy. Therefore, PEGylated hollow gold nanoparticles 
internalized within MSCs are efficient photothermal therapeutic agents on 
subcutaneous xenograft glioma. The immunohistochemical analysis revealed 
increased treatment efficiency in those tumors containing nanoparticles and receiving 
laser irradiation, especially on the group treated with nanoparticle-laden MSCs. The 
preferential accumulation of those carriers in the tumor blood vessels might be 
responsible for a homogeneous distribution along all the tumoral mass and a 
consequent efficient photothermal outcome. 
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Figures 
Figure 1  - Characterization of the photothermal nanoparticles 
(A) TEM images for Hollow Gold Nanospheres. Scale bars, 50 nm (top) and 20 nm 
(bottom). (B) STEM-HAADF images of Hollow Nanospheres. Scale bars, 20 nm 
(top) and 5 nm (bottom). (C) TEM images of PEG-Hollow Gold Nanospheres. The 
halo around the nanoparticles demonstrates the PEG coating. In this case, 
phosphotungstic acid was used to dye the polymer and allow TEM observation. Scale 
bars, 50 nm (left) and 20 nm (right). (D)  UV-Vis extinction spectra of HGNs and 
PEG-HGNs. 
Figure 2  - Cytotoxicity and cell trafficking studies 
A) Graphs showed AlamarBlue assays results for HGNs and PEG-HGNs, 
respectively. For the experiments with HGNs, 20 µg·mL
-1
 was chosen as the highest 
dose which did not induce cytotoxicity. For the PEG-HGNs case we used 50 µg·mL
-1
 
as limit of the sub-cytotoxic dose. (B) Dual Beam images demonstrate that the 
nanoparticles locate inside the cells. The two images above correspond to a MSC 
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photographs at different magnifications. In the bottom left image a cross section of a 
cell shows the presence of HGNs, the zoom showed in the right panel shows the 
morphology of those aggregates. EDX analysis on those aggregates corroborates the 
presence of Au inside the cell. Scale bars, 20 µm (top left), 10 µm (top right), 5 µm 
(bottom) and 300 nm (bottom).  
Figure 3  - Nanoparticle internalization within MSCs 
(A) Confocal Z-Stack. Scale bar: 75 µm. Red dots correspond to the HGNs in the cell 
after 24 h of incubation with PEG-HGNs. (B) SEM backscattered image. Scale bar: 
10 µm (left) and 5 µm (right). EDX revealed that the atomic composition of those 
aggregates corresponds to gold (results not shown). 
Figure 4  - Flow cytometry based kinetics of the internalization 
process  
(A) Nanoparticle internalization kinetics of HGNs (top) and PEG-HGNs (bottom). (B) 
Image of the flow cytometer showing control cells (top) and rhodamine labelled gold 
nanoparticles loaded within MSCs MSCs (bottom).   
Figure 5  - Photothermal therapy on HeLa cell-line xenograft 
tumors after intratumoral administration 
In vivo antitumoral activity on HeLa tumors. (A) Tumor size evolution over time for 
both treated and control groups. (B) Photographs of HeLa xenografts at day 12 after 
laser irradiation. It is important to point out that the projected laser-spot size was 
larger than the size of the projected area of the tumors.  
Figure 6  - Photothermal therapy on U251MG cell-line xenograft 
tumors after intravenous administration  
 (A) Tumor size evolution over time for both treated and control groups. The first 
arrow indicates the time in which HGNs or HGNs-loaded in MSCs were 
administered, the second and the third arrows show the time span in which the laser 
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irradiation took place. (B) Tumor area of the different groups at day 20 after the 
injection. The differences between control and the groups marked with * were 
statistically significant (P<0.05). (C) Photographs of U251MG xenografts at day 12 
after the first laser irradiation. It is important to point out that the projected laser-spot 
size used was larger than the size of the projected area of the tumors.  
Figure 7  - Hematoxilin-eosin staining results for histological 
sections recovered at the end of the experiment 
 (A-D). Ki-67 staining (E-F). (A) Control tumor (G1 group). Highly cellular 
pleomorphic neoplastic proliferation. H&E 10x. (B) PEG-HGNs+ laser treated tumor 
(G2 group). Multifocal necrotic areas on the tumor parenchyma. H&E 4x. (C) MSCs+ 
PEG-HGNs+ laser treated tumor (G3 group). Focally extensive necrotic area affecting 
most of the tumor parenchyma. H&E 4x. (D) MSCs+ PEG-HGNs (G4 group). Highly 
cellular, expansive neoplastic proliferation. H&E 4x. (E) Control tumor (G1 group). 
Positive staining for Ki-67 on 78% of neoplastic cells. IHQ 10x. (F) MSCs+ PEG-
HGNs+ laser treated (G3 group). Positive staining for Ki-67 on 59% of neoplastic 
cells. IHQ 10x. 
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Tables 
Table 1  - Immunohistochemical staining for Ki-67 expression on 
tumor cells 
Groups 
% Ki67 
positive cells 
% Ki67 
negative cells 
Control (G1) 78% 22% 
PEG-HGNs + laser (G2) 66% 34% 
MSCs + PEG-HGNs + laser (G3) 59% 41% 
MSCs + PEG-HGNs (G4) 76% 24% 
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Additional file 1 – Supplementary results  
Additional information is available in the Supplementary results section. 
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